Overview

Diverging from traditional neuro-centric treatment paradigms, we focus on activating the peripheral immune system to facilitate brain repair, offering novel treatment pathways. Our lead program employs IBC-Ab002, a proprietary anti-PD-L1 monoclonal antibody engineered for transient, intermittent PD-1/PD-L1 pathway blockade – enginered specifically for use in chronic neurodegenerative disease settings. The scientific foundation for our work is rooted in the groundbreaking research of Professor Michal Schwartz at the Weizmann Institute of Science, and is led by a team with deep expertise in neuroimmunology, immunology, neuroscience, and drug development.